Tag: MEDESIS
Medesis Pharma: progress against Alzheimer’s and capital increase
(AOF) – Medesis Pharma announces that it has “successfully reached a key milestone in its phase 2 clinical study for the treatment of Alzheimer’s disease”. The biotech developing drug candidates…
Medesis Pharma: progress against Alzheimer’s and capital increase – 01/29/2024 at 6:35 p.m.
(AOF) – Medesis Pharma announces that it has “successfully reached a key milestone in its phase 2 clinical study for the treatment of Alzheimer’s disease”. The biotech developing drug candidates…
Medesis Pharma: capital increase of 440,000 euros
(AOF) – Medesis Pharma announces the completion of a capital increase of 440,000 euros. The biotech developing drugs based on a proprietary technology for administering active ingredients in nano micelles…
Medesis Pharma: capital increase of 440,000 euros – 12/20/2023 at 6:21 p.m.
(AOF) – Medesis Pharma announces the completion of a capital increase of 440,000 euros. The biotech developing drugs based on a proprietary technology for administering active ingredients in nano micelles…
MEDESIS PHARMA: ACTIVITIES & RESULTS OF THE 1ST HALF 2023 – 10/27/2023 at 6:00 p.m.
Montpellier, October 27, 2023 at 6:00 p.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for administering active ingredients in nano micelles orally,…
Medesis Pharma seeking new financing – 10/27/2023 at 6:15 p.m.
(AOF) – Medesis Pharma announces that its cash flow as of June 30, 2023 amounts to 139,000 euros, which gives it visibility “until the end of November 2023”. The biotech…
Medesis Pharma seeking new financing
(AOF) – Medesis Pharma announces that its cash flow as of June 30, 2023 amounts to 139,000 euros, which gives it visibility “until the end of November 2023”. The biotech…
MEDESIS PHARMA: PUBLICATION OF A SCIENTIFIC ARTICLE IN THE JOURNAL OF ALZHEIMER’S DISEASE ON THE USE OF LITHIUM FOR THE TREATMENT OF ALZHEIMER’S DISEASE – 10/11/2023 at 6:00 p.m.
Montpellier, October 11, 2023 at 6:00 p.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company, developing drug candidates based on its proprietary technology for administering active ingredients in nano micelles orally,…
Medesis Pharma: opening of a safeguard procedure – 03/10/2023 at 6:29 p.m.
(AOF) – Medesis Pharma announces receipt of the judgment of the Montpellier Commercial Court granting it the opening, on September 29, 2023, of a safeguard procedure. This biotech developing drug…
Medesis Pharma presents a poster at the AAIC international conference
By Alexandra Saintpierre Published on 07/14/2023 at 2:52 p.m. Photo credit © NissierPictures (Boursier.com) — The pharmaceutical biotechnology…
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE INTERNATIONAL CONFERENCE OF THE ALZHEIMER ASSOCIATION IN AMSTERDAM – 07/13/2023 at 18:00
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE INTERNATIONAL CONFERENCE OF THE ALZHEIMER ASSOCIATION IN AMSTERDAM Final recruitment stage of the Nanolithium study in the fall of 2023, first results…
Medesis: Invest Securities maintains its advice
(CercleFinance.com) – Invest Securities announces this morning that it is maintaining its ‘neutral’ advice on the Medesis share, with an unchanged price target of 3.3 euros. While the Commercial Court…